A vs BIO
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide.
Side-by-side fundamentals
| Metric | A | BIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $133.46 | $305.96 | |
| Market cap as of 2026-07-23 | $37.6B | $8.2B | |
| P/E as of 2026-07-23 | 26.62 | 48.82 | A lower |
| PEG as of 2026-07-23 | 3.24 | n/a | |
| Net margin as of 2026-07-23 | +19.6% | +6.5% | A higher |
| Gross margin as of 2026-07-23 | +52.9% | +51.8% | A higher |
| Operating margin as of 2026-07-23 | +21.5% | +2.0% | A higher |
| ROE as of 2026-07-23 | +20.8% | +2.4% | A higher |
| ROA as of 2026-07-23 | +11.1% | +1.7% | A higher |
| Debt / equity as of 2026-07-23 | 0.47 | 0.18 | BIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.1% | +1.9% | A higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | -2.7% | A higher |
| Dividend yield as of 2026-07-23 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 1.24 | 1.06 | |
| 1-year return as of 2026-07-22 close | +18.6% | +24.6% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.